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Background: Allergen-speciﬁc sublingual immunotherapy is a potential disease-modifying treatment for
allergic asthma. Galectin-9 (Gal-9), a b-galactoside-binding protein with various biologic effects, acts as
an immunomodulator in excessive immunologic reactions by expanding regulatory T cells (Treg) and
enhancing transforming growth factor (TGF)-b signaling. We investigated the efﬁcacy of sublingually
administered Gal-9 as an adjuvant to a speciﬁc allergen in a Dermatophagoides farinae (Df)-induced
mouse model of chronic asthma.
Methods: BALB/c mice were intranasally sensitized with Df extract 5 days/week for 5 weeks, and then
sublingual Df-allergen extract for 2 weeks (5 days/week). Three days after the ﬁnal sublingual treatment,
mice were intranasally challenged with Df extract. The early asthmatic response (EAR) was evaluated
5 min after the last Df challenge. Airway hyperresponsiveness (AHR) was assayed and bronchoalveolar
lavage (BAL) was performed 24 h after the last allergen challenge. Serum IgE and cytokine levels, and
number of inﬂammatory cells in the BAL ﬂuid (BALF) were analyzed.
Results: Sublingual Df treatment in the presence of Gal-9, but not alone, signiﬁcantly reduced AHR; EAR;
number of eosinophils and interleukin-13 in the BALF; and serum IgE levels. BALF TGF-b1 levels were
signiﬁcantly increased in the presence of Gal-9 compared with Df alone. Treg depletion blocked the
inhibitory effects of Gal-9 on the EAR, AHR, eosinophilic airway inﬂammation, and Df-speciﬁc serum IgE
levels, and suppressed BALF TGF-b1 levels.
Conclusions: Gal-9 exhibited beneﬁcial effects of sublingual Df allergen-speciﬁc immunotherapy in a
Df-induced mouse model of chronic asthma, possibly by Gal-9-induced TGF-b1 production in the lung.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Asthma is a common respiratory disease characterized by
reversible airway obstruction, airway hyperresponsiveness (AHR),
and chronic airway inﬂammation with eosinophils. The majority of
patients with asthma are well controlled by combined treatment
with inhaled corticosteroids, long-acting b-agonists, and leuko-
triene receptor antagonists.1e3 These drugs have anti-inﬂammatory
effects on chronic airway inﬂammation, but do not cure asthma.
While allergen-speciﬁc immunotherapy might cure asthma, someMedicine, Kawasaki Medical
92, Japan.
. Katoh).
ety of Allergology.
rgology. Production and hosting by Else
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model of chronic asthproblems, such as the administration route of the allergen, must be
overcome.4 Recently, patients with allergic rhinitis and asthma
induced by mite-allergen were treated with an allergen-speciﬁc
sublingual immunotherapy (SLIT). The SLIT route could be beneﬁ-
cial toward curing these allergic airway diseases, but some difﬁ-
culties remain.5,6
Galectin-9 (Gal-9) is a b-galactoside binding animal lectin that
induces various biologic reactions, such as cell chemoattraction,
activation, and apoptosis.7 Gal-9 functions as an immunomodulator
in excessive immunologic reactions by expanding regulatory T cells
(Treg) and immunosuppressive macrophages.8e10 Furthermore,
Gal-9 and CD44 interactions enhance the stability and function of
adaptive Treg through smad3-dependentmechanisms.11 The role of
Gal-9 in allergic respiratory diseases, however, remains unclear.vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
of Galectin-9 on allergen-speciﬁc sublingual immunotherapy in a
ma, Allergology International (2016), http://dx.doi.org/10.1016/
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allergen-induced chronic asthma using the Dermatophagoides far-
inae (Df)-induced murine model of chronic asthma that we previ-
ously developed.12We also used recombinant stable human Gal-913
as an adjuvant to the mite-allergen. The additive effects of Gal-9 in
this SLIT model were evaluated by physiological examination,
eosinophilic airway inﬂammation, and serum allergen-speciﬁc
immunoglobulin levels, especially immunoglobulin IgE.
Methods
Animal model and sublingual immunotherapy
BALB/c mice were obtained from Charles River Laboratory
(Yokohama, Japan). Female mice (8e12 weeks old) were intrana-
sally sensitized with Df extract (40 ml of 1 mg/ml, LSL, Tokyo, Japan)
5 days/week for 5 weeks (Fig. 1). Negative control animals were
intranasally exposed to phosphate-buffered saline (PBS) in a similar
manner. Following intranasal administration of the Df extract for 5
weeks, SLIT was performed 5 days/week, twice daily, for 2 weeks
(Fig. 1). The SLIT agents were PBS, Df-allergen extract (250 mg/day,
Torii, Tokyo, Japan), and Df-allergen extract with recombinant hu-
man stable Gal-9 (0.1, 0.3, or 1.0 mg [3 mM], GalPharma, Takamatsu,
Japan).13 For SLIT, the mouth of an anesthetized mouse was kept
open by placing forceps under the tongue. We administered 10 ml of
SLIT agent under the tongue with a micropipette that was kept in
place for 1 min. In preliminary experiments, we used trypan blue to
conﬁrm that this method does not deliver the SLIT agent to the
stomach or lung. Endotoxin contamination in the Df and Gal-9
solution was minimal, as previously described (<0.25 EU/mg).13,14
In this SLIT model, intranasal Df exposure is stopped during the
SLIT because it is important for the SLIT to prevent allergen contact
in patients with atopic asthma, as previously described.15,16 All
experiments in the present study were performed under a protocol
approved by the Institutional Animal Care and Use Committee of
the Kawasaki Medical School.
Early asthmatic response (EAR) and airway hyperresponsiveness
(AHR)
The early asthmatic response (EAR) was evaluated as the rate of
increase (DsRaw) in airway resistance (sRaw) after the last Df
challenge, compared with PBS exposure just before the last Df
challenge in each mouse using a two-chambered, double-ﬂow
plethysmograph system (Pulmos; M.I.P.S., Osaka, Japan). We
monitored DsRaw for 5 min after the last Df challenge. To investi-
gate AHR, micewere forced to inhale PBS or acetyl-b-methylcholineFig. 1. Animal model and sublingual immunotherapy. BALB/c mice were intranasally sensit
weeks. Negative control animals were intranasally exposed to PBS in a similar manner. Fol
(SLIT) was performed 5 days/week, twice daily, for 2 weeks. Early asthmatic response (EAR
(AHR) and bronchoalveolar lavage (BAL) were evaluated on day 51, 24 h after the last Df (8
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tions of 3, 6, or 12.5 mg/ml. We measured sRaw in awake mice
using the two-chambered, double-ﬂow plethysmograph system.
Forced inhalation was administered for 3 min. After a 1-min rest,
sRaw was measured for 2 min. AHR is expressed as the concen-
tration of Mch required to provoke a doubling of sRaw (PC200), like
PC20 in patients with asthma.
Collection of blood, bronchoalveolar lavage ﬂuid (BALF), and lung
tissue
After euthanasia, blood and bronchoalveolar lavage ﬂuid (BALF)
were collected, and the lungs were removed for pathologic evalu-
ation by hematoxylin and eosin (HE) and Periodic acid-Schiff (PAS)
staining. Mucus score was estimated by PAS-stained lung. A total of
10 airways of three mice from each group were categorized ac-
cording to the abundance of PAS goblet cells, and assigned nu-
merical scores (0 ¼ <5% goblet cells; 1 ¼ 5e25%; 2 ¼ 25e50%;
3 ¼ 50e75%; 4 ¼ >75%). Bronchoalveolar lavage (BAL) was per-
formed 24 h after the last allergen administration, and BALF was
obtained by washing the lungs with 4  1 ml of PBS and centri-
fuged. The supernatant of the ﬁrst wash was stored at 80 C until
use. Cell pellets of all washes were collected and resuspended in
1 ml PBS. The number of BALF cells was counted using a cell
counter. Cytospin slides were stainedwith Diff-Quik (Sysmex, Kobe,
Japan). Differential cell counts were performed on at least 400 cells.
Enzyme-linked immunosorbent assay (ELISA)
Amounts of interleukin (IL) -5, IL-10, IL-13, interferon-g (IFN-g),
and transforming growth factor (TGF)-b1 (R&D Systems, Minne-
apolis, MN, USA) in the BALF were measured using an enzyme-
linked immunosorbent assay (ELISA). The detection limits were
7.0 pg/mL for IL-5, 2.0 pg/mL for IL-10, 3.9 pg/mL for IL-13, 4.7 pg/
mL for IFN-g, and 4.9 pg/mL for TGF-b1. Concentrations below the
detection limits were assumed to be zero for statistical analysis. Df-
speciﬁc serum IgE was measured by ELISA as previously
described.14 Brieﬂy, diluted sera were incubated in Df extract-
coated plates, followed by incubation with biotin-conjugated an-
tibodies against IgE (Serotec, Raleigh, NC, USA) and streptavidin-
horseradish peroxidase (Invitrogen, Carlsbad, CA, USA). The Df-
speciﬁc serum IgE levels were expressed as relative absorbance
units (optical density at 450 nm). For detection of Df-speciﬁc serum
IgG1, and IgG2a, either biotinylated IgG1 (Southern Biotech, Bir-
mingham, AL, USA) or IgG2a (BD Biosciences, San Jose, CA, USA)was
used. Levels of Df-speciﬁc IgG1 and IgG2a were expressed as po-
tency (%), which was calculated using the ﬂuorescence intensityized with Dermatophagoides farinae (Df) extract (40 ml of 1 mg/ml) 5 days/week for 5
lowing intranasal administration of Df extract for 5 weeks, sublingual immunotherapy
) was evaluated on day 50 just after the last Df challenge. Airway hyperresponsiveness
0 ml: 40 ml twice of 1 mg/ml) challenge.
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negative control)/(positive control  negative control)  100. The
pooled serum of Df-sensitized mice was used as a positive control.
Evaluation of Treg
Treg in the BALF and spleen were measured using a mouse Treg
staining kit (eBioscience, San Diego, CA, USA) using a FACSCalibur®
ﬂow cytometer (BD Biosciences, San Jose, CA, USA). For Treg
depletion, mice were intraperitoneally injected with PC61 mono-
clonal antibody (mAb, 250 mg/mouse) 3 days before the starting
SLIT (day 33). Treg depletion was conﬁrmed by evaluating the
spleen for CD4, CD25, and Foxp3 expression using ﬂow cytometry.
CD25 was detected using an anti-CD25 mAb that recognizes an
epitope distinct from that of the PC61 mAb. Rat IgG was used as a
negative control. As previously described,18 no CD4þCD25þ
Foxp3þ cells were detected in the spleen during SLIT for 2 weeks
(day 36eday 51) after PC61-treatment (day 33), whereas these cells
were detected in the spleen after Rat IgG-treatment (day 33). PC61
was obtained as a kind gift from Eiichi Nakayama (Kawasaki Uni-
versity of Medical Welfare, Kurashiki, Japan). Rat IgG was obtained
from R&D systems.
Statistical analysis
All data are expressed as the mean ± standard error (SEM).
Statistical analysis was performed using GraphPad Prism version
6.0 for Windows (GraphPad Software, San Diego, CA, USA). The
KruskaleWallis test with Dunn's multiple comparisons test or the
ManneWhitney U test was used to compare values between two
groups. Differences with probability values of less than 0.05 were
considered signiﬁcant.
Results
Effects of Gal-9 on EAR and AHR in mite allergen-speciﬁc SLIT
To evaluate the effect of Gal-9 on SLIT, we develop a SLIT model
using the previously reported Df-allergen and Df-induced mouse
model of chronic asthma (Fig. 1). This model exhibits EAR, AHR,
chronic eosinophilic airway inﬂammation, Df-speciﬁc IgE, andFig. 2. Effects of Gal-9 on early asthmatic response (EAR) and airway hyperresponsivene
resistance change from PBS exposure (%) as described in the Methods. Airway hyperrespon
means ± SEM. Values shown are means from 12 mice per group. These results are typical of
compare values of different groups followed by Dunn's multiple comparisons test. *p < 0.05
#p < 0.05 compared with Df-sensitization (þ), SLIT: Df () Gal-9 (), and Df-challenge (þ)
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investigated the efﬁcacy of increasing concentrations of sub-
lingually administered Gal-9 as an adjuvant to a speciﬁc allergen in
this model. We ﬁrst evaluated the EAR after exposure to a speciﬁc
allergen. The airway resistance change from PBS exposure (%) at
5 min after intranasal Df challenge and AHR at 24 h after intranasal
Df challenge were measured. Sublingual Df treatment alone did not
signiﬁcantly affect EAR and AHR, but the EAR and AHR levels ten-
ded to be lower compared with that after PBS treatment alone
(p ¼ 0.1840 and p ¼ 0.0534, respectively, Fig. 2). Sublingual Df
treatment in the presence of Gal-9 signiﬁcantly reduced both EAR
and AHR (p < 0.05, Fig. 2). Further, sublingual Gal-9 treatment alone
did not signiﬁcantly affect EAR and AHR as compared with the PBS
treatment alone group (Supplementary Fig. 1A).
Effects of Gal-9 on airway eosinophilic inﬂammation in mite
allergen-speciﬁc SLIT
To evaluate the efﬁcacy of Gal-9 on eosinophilic airway
inﬂammation in the SLIT model, we examined inﬂammatory cell
numbers in the BALF and histopathologic ﬁndings. Numbers of
inﬂammatory cells in the BALF were counted 24 h after the intra-
nasal allergen challenge. Numbers of total leukocytes and eosino-
phils, but not lymphocytes, neutrophils, and macrophages, were
signiﬁcantly reduced by SLIT in the presence of Gal-9 (p < 0.05,
Fig. 3A), but not Df-alone. SLIT with Gal-9 by itself had no effect on
eosinophilic airway inﬂammation (Supplementary Fig. 1B). Histo-
pathologic examination of the lung tissue indicated that peri-
bronchial and perivascular eosinophilic inﬁltration induced by Df-
challenge was suppressed by SLIT, especially in the presence of
Gal-9 (Fig. 3B). Furthermore, to examine the effect of SLIT on mucus
secretion in the airway, we evaluated PAS-stained lung sections.
Allergen-induced mucus-secreting goblet cells were relatively
suppressed by SLIT with Gal-9, especially in a low dose of Gal-9
(0.1 mg; p ¼ 0.0008, 0.3 mg; p ¼ 0.3683, 1.0 mg; p ¼ 0.5483, Fig. 3C).
Gal-9 decreases Th2 cytokine levels in the BALF as well as serum IgE
levels in the SLIT model
To investigate the mechanisms of the anti-inﬂammatory effects
of Gal-9 in the SLIT model, we measured the concentrations of IL-5ss (AHR) in mite allergen-speciﬁc SLIT. EAR was evaluated and expressed as airway
siveness (AHR) was measured and expressed as PC200 sRaw (mg/ml). Data represent
those obtained in three independent experiments. The KruskaleWallis test was used to
compared with Df-sensitization (), SLIT: Df () Gal-9 (), and Df-challenge () group.
group.
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AB
Fig. 4. Effects of Gal-9 on Th2 cytokine levels in the BALF and serum immunoglobulin levels in the SLIT model. IL-5 and IL-13 levels in the BALF (A), and Df-speciﬁc IgE, IgG1, and
IgG2a titers in the serum (B)were determined by ELISA. The detection limit was 7.0 pg/mL for IL-5 and 3.9 pg/mL for IL-13. Concentrations below the detection limits were assumed
to be zero for statistical analysis. Data represent means ± SEM. Values shown are means from 12 mice per group. These results are typical of those obtained in three independent
experiments. The KruskaleWallis test was used to compare values of different groups followed by Dunn's multiple comparisons test. *p < 0.05 compared with Df-sensitization (),
SLIT: Df () Gal-9 (), and Df-challenge () group. #p < 0.05 compared with Df-sensitization (þ), SLIT: Df () Gal-9 (), and Df-challenge (þ) group.
Fig. 3. Effects of Gal-9 on airway inﬂammation and remodeling in mite allergen-speciﬁc SLIT. Absolute numbers of inﬂammatory cells in the bronchoalveolar ﬂuid (BALF) were
estimated (A). Data represent means ± SEM. Values shown are means from 12 mice per group. These results are typical of those obtained in three independent experiments. (B).
Histologic examination of formalin-ﬁxed lung sections stained with hematoxylin and eosin (original magniﬁcation: upper panels, 100; lower panels, 1000). Arrows indicate
eosinophils. These results are typical of those obtained in three independent experiments. Mucus score was determined as described in the Methods. A total of 10 airways of three
mice from each group were analyzed (C). The KruskaleWallis test was used to compare values of different groups followed by Dunn's multiple comparisons test. *p < 0.05 compared
with Df-sensitization (), SLIT: Df () Gal-9 (), and Df-challenge () group. #p < 0.05 compared with Df-sensitization (þ), SLIT: Df () Gal-9 (), and Df-challenge (þ) group.
Fig. 5. Effects of Gal-9 on Treg in the BALF in the SLIT model. TGF-b1 concentration and CD4þCD25þFoxp3high cell number in the BALF were determined by ELISA and ﬂowcy-
tometry, respectively. The detection limit was 4.9 pg/mL for TGF-b1. Concentrations below the detection limits were assumed to be zero for statistical analysis. Data represent
means ± SEM. Values shown are means from 12 mice per group. These results are typical of those obtained in three independent experiments. The KruskaleWallis test was used to
compare values of different groups followed by Dunn's multiple comparisons test. *p < 0.05 compared with Df-sensitization (), SLIT: Df () Gal-9 (), and Df-challenge () group.
#p < 0.05 compared with Df-sensitization (þ), SLIT: Df () Gal-9 (), and Df-challenge (þ) group.
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concentrations of IL-5 in the BALF were reduced by SLIT in the
presence or absence of Gal-9 (p < 0.05, Fig. 4A). The IL-13 concen-
tration in the BALFwas signiﬁcantly reduced by SLIT in the presence
of low and medium doses of Gal-9 (p < 0.05, Fig. 4A). Furthermore,
low and medium doses of Gal-9 suppressed the production of Df-
speciﬁc IgE levels in the serum (p < 0.05, Fig. 4B). Serum levels of
Df-speciﬁc IgG1 tended to be lower in the presence of low
(p¼ 0.1071, Fig. 4B) andmedium (p¼ 0.1826, Fig. 4B) doses of Gal-9.
The serum levels of Df-speciﬁc IgG2a did not differ signiﬁcantly
among treatments (Fig. 4B). Further, SLIT with Gal-9 by itself had no
effect on the BALF Th2 cytokine and serum Df-speciﬁc IgE levels
(Supplementary Fig. 1C). The production of TGF-b1 in the BALF was
signiﬁcantly increased in this SLIT model. The TGF-b1 level was
higher in the presence of lowandmediumdoses of Gal-9 thanwhen
Df alonewas administered (p¼ 0.0526 and p¼ 0.0061, respectively,
Fig. 5). IL-10 and IFN-g were not detected in the BALF of this SLIT
model (data not shown). The number of CD4þCD25þFoxp3high Treg
in the BALF was signiﬁcantly increased by sublingual Df treatment
in the presence of Gal-9 (p < 0.05, Fig. 5), but not Df-alone.
Efﬁcacy of Gal-9 on the SLIT model was blocked by Treg depletion
To deplete Treg during SLIT, PC61 anti-CD25 mAb was injected
3 d before the starting SLIT, as described in the Methods. PC61
treatment diminished the inhibitory effects of Gal-9 on EAR and
AHR (p < 0.05, Fig. 6A). PC61 treatment blocked the Gal-9 SLIT-
induced decrease in the number of eosinophils, IL-5 and IL-13
concentrations in the BALF, and serum IgE levels (p < 0.05,
Fig. 6B). PC61 treatment by itself had no effect on asthmatic re-
sponses in this SLIT model (Fig. 6A and B). Further, PC61 treatment
suppressed the Gal-9 SLIT-induced increase in the concentration of
TGF-b1 in the BALF (p < 0.05, Fig. 6C).
Discussion
The present ﬁndings demonstrated that Gal-9 enhanced the
efﬁcacy of SLIT in a mouse model of chronic asthma induced by the
Df allergen. In this treatment strategy, novel SLIT using Gal-9 as an
adjuvant improved the pathophysiology of asthma. The treatment
in the presence of Gal-9, but not in the absence of Gal-9, signiﬁ-
cantly reduced both the EAR and AHR. Furthermore, both BALF IL-
13 levels and serum Df-speciﬁc IgE levels were signiﬁcantly
reduced by Gal-9 as an adjuvant to the Df allergen. Gal-9 also
inhibited the eosinophilic airway inﬂammation associated with
decreased levels of the Th2 cytokines, IL-5 and IL-13.
Asthma is a common respiratory disease in humans, and more
than half of patients with asthma have allergen-speciﬁc IgE.3 House
dust mites are one of the most common aeroallergens in asthma.3
While inhaled corticosteroids control asthmatic symptoms well,
they are not able to cure the disease. SLIT is a disease-modifying
treatment for respiratory allergies,19 but the beneﬁt and effect
may not be very substantial, and the treatment requires a long
period of therapy and high amounts of the allergen. Further, it is
difﬁcult to diminish allergen-speciﬁc IgE production using SLIT.20,21
Inhalation of a speciﬁc allergen might exacerbate asthma, even if
asthmatic symptoms are well controlled. To cure asthma, it is
important to suppress the production of allergen-speciﬁc IgE.
Previous studies demonstrated the preventive effects of SLIT in a
mite allergen-induced acute murine asthmamodel by several timesFig. 6. Efﬁcacy of Gal-9 on the SLIT model was blocked by Treg depletion. Early asthmatic r
eosinophils and concentration of IL-5, and IL-13 in the BALF and Df-speciﬁc IgE levels in the
Data represent means ± SEM. Values shown are means from 8 mice per group. These result
comparisons were examined by ManneWhitney U test.
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study, we use an established model of chronic severe asthma by 25
times intranasal sensitization without alum in mice similar to hu-
man chronic asthma in adults,12 and attempted to cure this disease
model by SLIT using Gal-9 as an adjuvant. Recently, Shima et al.
reported that SLIT using high-dose Df extract (5 mg/day, Torii)
ameliorates AHR and eosinophilic airway inﬂammation, but not
serum IgE levels in an asthmatic mouse model.17 In the present
study, we demonstrated that our new SLIT using a low dose of the
same allergen (250 mg/day, Torii) with Gal-9 is more effective in a
similar asthmatic mouse model. Df-speciﬁc IgE levels in the serum
were signiﬁcantly reduced by sublingual Df treatment in the
presence of Gal-9, but not in the absence of Gal-9. Further, allergen-
induced EAR and AHR were signiﬁcantly suppressed by Gal-9 as an
adjuvant to the Df allergen. These ﬁndings suggest that adminis-
tration of Gal-9 enhances the efﬁcacy of SLIT in mite allergen-
induced asthma and might contribute to cure this disease.
SLIT induces elevated levels of IL-10 and IgG4 in the serum of
patients with allergic airway diseases.21,22 Treg are thought to play
an important role in the SLIT. Recent studies demonstrated that
Gal-9 acts an immunomodulator in excessive immunologic re-
actions by expanding Treg and enhancing TGF-b signaling.10,11 In
the present study, we evaluated the regulation mechanism of the
effect of Gal-9 on SLIT in addition to a speciﬁc allergen. Gal-9 may
suppress eosinophilic airway inﬂammation by inhibiting IL-5 pro-
duction in the lung or inducing apoptosis.23,24 Further, Gal-9 sup-
pressed Df-speciﬁc IgE production by inhibiting IL-13 production,
especially at low and medium doses. Next, we evaluated the levels
of inhibitory cytokines in the BALF of the SLIT model. Levels of TGF-
b1, but not IL-10 in the BALF were increased in sublingual Df-
treated mice with low and medium doses of Gal-9 in this SLIT
model. Further, numbers of CD4þCD25þFoxp3high Treg in the BALF
were also increased by SLIT in the presence of Gal-9. TGF-b1 and
CD4þCD25þFoxp3high Treg induced by Gal-9 in the lungmight play
an important role in the effects of Gal-9 on SLIT. Further studies are
required to clarify the mechanisms of the adjuvant effects of Gal-9
in this SLIT model.
Gal-9 is a ligand for CD44 that blocks the binding between CD44
and its original ligand hyaluronan.25,26 Interestingly, Gal-9 binds
CD44 expressed on Treg and enhances TGF-b signaling.11 Previous
studies demonstrated that a medium dose of Gal-9 (1 mM) is suf-
ﬁcient to bind CD44 and a high dose of Gal-9 (3 mM) induces
apoptosis of Th1 cells through Tim-3 signaling, and induces
apoptosis of IL-5 activated human eosinophils by an unknown
ligand.23,26,27 The inhibitory effect of Gal-9 on IL-13 and Df-IgE
production, and Gal-9 induction of TGF-b1 were weaker at a high
dose (3 mM) than at low (0.3 mM) and medium (1 mM) doses. The
effects of Gal-9 on inﬂammatory cells may differ depending on the
Gal-9 concentration by acting on a different ligand.
Treg can be depleted by treatment with PC61 anti-CD25 mAb.18
To conﬁrm the Treg-dependent inhibitory effects of Gal-9 in this
SLITmodel, Tregwere depletedwith PC61 pretreatment during SLIT
as described in the Methods. As previously described,18 during SLIT
for 2 weeks, no CD4þCD25þFoxp3þ Treg were observed in the
spleens of PC61-treated mice, whereas CD4þCD25þFoxp3þ Treg
were observed in the spleens of Rat IgG-treated mice (data not
shown). We used a low dose of Gal-9 to evaluate the contribution of
Treg in the SLITmodel, because a low dose of Gal-9 is more effective
to induce TGF-b1 in the BALF than a high dose. The increase TGF-b1
levels in the BALF of Gal-9 SLIT mice was diminished by PC61esponse (EAR) and airway hyperresponsiveness (AHR) were evaluated (A). Number of
serum were determined (B). Concentration of TGF-b1 in the BALF was determined (C).
s are typical of those obtained in three independent experiments. Between two-group
of Galectin-9 on allergen-speciﬁc sublingual immunotherapy in a
ma, Allergology International (2016), http://dx.doi.org/10.1016/
M. Ikeda et al. / Allergology International xxx (2016) 1e88pretreatment. The inhibitory effects of Gal-9 on EAR and AHR, and
eosinophilic airway inﬂammation in this SLIT model were also
diminished by PC61 pretreatment compared with Rat IgG pre-
treatment. Finally, the inhibitory effects of Gal-9 on the production
of Df-speciﬁc IgE in the serum were abolished by PC61-
pretreatment. PC61 treatment may deplete not only CD4þ
CD25þTreg, but also CD4þCD25þ activated T cells. If the
CD4þCD25þ activated T cells were mainly depleted by PC61 treat-
ment, it would indicate that the Th2-mediated eosinophilic airway
inﬂammationwas decreased. The Th2mediated eosinophilic airway
inﬂammation, however, was increased by PC61 treatment. In this
model, the effects of Treg depletion were mainly observed, even if
activated Tcellswere also depleted. Further, PC61 treatment by itself
and SLITwith Gal-9 by itself had no effect on asthmatic responses in
this SLITmodel. These data suggest that the inhibitory effects of Gal-
9 on asthmatic responses are Treg and Df allergen-dependent.
Further studies are required to clarify the mechanisms of inhibi-
tory effects of Gal-9 including TGF-b1 production in detail.
In conclusion, Gal-9 inhibited not only Th2-related eosinophilic
airway inﬂammation, but also allergen-induced EAR and allergen-
speciﬁc IgE production in this SLIT model. SLIT using Gal-9 as an
adjuvant might cure asthma more effectively than SLIT without
Gal-9, and Gal-9 is an adjuvant that might shorten the therapy
period and reduce the amount of allergen required in the SLIT.
Acknowledgements
The authors thank Ms. Mariko Takaya, and Ms. Tae Uesaka for
their skillful assistance. This work was supported in part by JSPS
KAKENHI JP26461205 and by the Project Research Grants from
Kawasaki Medical School.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.alit.2016.10.007.
Conﬂict of interest
AH and KO-D are employees of Torii Pharmaceutical Co., Ltd. The rest of the
authors have no conﬂict of interest.
Authors' contributions
SK, KO-D, and MO designed the study. MI, AH, HS, and SK performed the ex-
periments. MI and SK wrote the paper.
References
1. Busse WW, Lemanske Jr RF. Asthma. N Engl J Med 2001;344:350e62.
2. Bousquet J, Mantzouranis E, Cruz AA, Aït-Khaled N, Baena-Cagnani CE,
Bleecker ER, et al. Uniform deﬁnition of asthma severity, control, and exacer-
bations: document presented for the World Health Organization Consultation
on Severe Asthma. J Allergy Clin Immunol 2010;126:926e38.
3. Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol
2015;165:45e56.
4. Moreno C, Cuesta-Herranz J, Fernandez-Tavora L, Alvarez-Cuesta E. Immuno-
therapy Committee, Sociedad Espa~nola de Alergología e Inmunología Clínica.
Immunotherapy safety: a prospective multi-centric monitoring study of bio-
logically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy
2004;34:527e31.Please cite this article in press as: Ikeda M, et al., Beneﬁcial effects
Dermatophagoides farinae-induced mouse model of chronic asth
j.alit.2016.10.0075. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune
mechanisms of allergen-speciﬁc sublingual immunotherapy. Allergy 2006;61:
151e65.
6. Frew AJ. Sublingual immunotherapy. N Engl J Med 2008;358:2259e64.
7. Hirashima M, Kashio Y, Nishi N, Yamauchi A, Imaizumi TA, Kageshita T, et al.
Galectin-9 in physiological and pathological conditions. Glycoconj J 2004;19:
593e600.
8. Seki M, Oomizu S, Sakata KM, Sakata A, Arikawa T, Watanabe K, et al. Galectin-9
suppresses the generation of Th17, promotes the induction of regulatory T
cells, and regulates experimental autoimmune arthritis. Clin Immunol
2008;127:78e88.
9. Arikawa T, Saita N, Oomizu S, Ueno M, Matsukawa A, Katoh S, et al. Galectin-9
expands immunosuppressive macrophages to ameliorate T-cell-mediated lung
inﬂammation. Eur J Immunol 2010;40:548e58.
10. Oomizu S, Arikawa T, Niki T, Kadowaki T, Ueno M, Nishi N, et al. Cellsurface
galectin-9 expressing Th cells regulate Th17 and Foxp3þ Treg development by
Galectin-9 secretion. PLoS One 2012;7:e48574.
11. Wu C, Thalhamer T, Franca RF, Xiao S, Wang C, Hotta C, et al. Galectin-9-CD44
interaction enhances stability and function of adaptive regulatory T cells. Im-
munity 2014;41:270e82.
12. Ikeda M, Katoh S, Shimizu H, Oka M. Development of two types of mite-
allergen induced murine model of chronic asthma with different severity.
Kawasaki Med J 2016;42:1e7.
13. Nishi N, Itoh A, Fujiyama A, Yoshida N, Araya S, Hirashima M, et al. Develop-
ment of highly stable galectins: truncation of the linker peptide confers
protease-resistance on tandem-repeat type galectins. FEBS Lett 2005;579:
2058e64.
14. Katoh S, Kaminuma O, Hiroi T, Mori A, Ohtomo T, Maeda S, et al. CD44 is critical
for airway accumulation of antigen-speciﬁc Th2, but not Th1, cells induced by
antigen challenge in mice. Eur J Immunol 2011;41:3198e207.
15. Yu H-Q, Li X-H, Guo H, Liu Z-G, Ran P-X, Ji K-M, et al. Sublingual immuno-
therapy efﬁcacy of Dermatophagoides farinae vaccine in a murine asthma
model. Int Arch Allergy Immunol 2010;152:41e8.
16. Hagner S, Rask C, Brimnes J, Andersen PS, Raifer H, Renz H, et al. House dust
mite-speciﬁc sublingual immunotherapy prevents the development of allergic
inﬂammation in a mouse model of experimental asthma. Int Arch Allergy
Immnunol 2016;170:22e34.
17. Shima K, Koya T, Tsukioka K, Sakagami T, Hasegawa T, Fukano C, et al. Effects of
sublingual immunotherapy in a murine asthma model sensitized by intranasal
administration of house dust mite extracts. Allergol Int 2016. http://dx.doi.org/
10.1016/j.alit.2016.05.012.
18. Setiady YY, Coccia JA, Park PU. In vivo depletion of CD4þFOXP3þ Treg cells by
the PC61 anti-CD25 monoclonal antibody is mediated by FcgRIIIþ phagocytes.
Eur J Immunol 2010;40:780e6.
19. Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for
allergic rhinitis? J Allergy Clin Immunol 2016;137:339e49.
20. Bergmann KC, Demoly P, Worm M, Fokkens WJ, Carrillo T, Tabar AI, et al. Ef-
ﬁcacy and safety of sublingual tablets of house dust mite allergen extracts in
adults with allergic rhinitis. J Allergy Clin Immunol 2014;133:1608e14.
21. Nolte H, Maloney J, Nelson HS, Bernstein DI, Lu S, Li Z, et al. Onset and dose-
related efﬁcacy of house dust mite sublingual immunotherapy tables in an
environmental exposure chamber. J Allergy Clin Immunol 2015;135:
1494e501.
22. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on
allergy immunotherapy: American academy of allergy, asthma & immunology/
European academy of allergy and clinical immunology/PRACTALL consensus
report. J Allergy Clin Immunol 2013;131. 1288e96.e3.
23. Katoh S, Nobumoto A, Matsumoto N, Matsumoto K, Ehara N, Niki T, et al.
Involvement of galectin-9 in lung eosinophilia in patients with eosinophilic
pneumonia. Int Arch Allergy Immunol 2010;153:294e301.
24. Katoh S, Oomizu S, Niki T, Shimizu H, Obase Y, Korenaga M, et al. Possible
regulatory role of galectin-9 on Ascaris suum-induced eosinophilic lung
inﬂammation in mice. Int Arch Allergy Immunol 2012;158(Suppl. 1):58e65.
25. Miyake K, Underhill CB, Lesley J, Kincade PW. Hyaluronate can function as a cell
adhesion molecule and CD44 participates in hyaluronate recognition. J Exp Med
1990;172:69e75.
26. Katoh S, Ishii N, Nobumoto A, Takeshita K, Dai SY, Shinonaga R, et al. Galectin-9
inhibits CD44-hyluronan interaction and suppresses a murine model of allergic
asthma. Am J Respir Crit Care Med 2007;176:27e35.
27. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The tim-3
ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol
2005;6:1245e52.of Galectin-9 on allergen-speciﬁc sublingual immunotherapy in a
ma, Allergology International (2016), http://dx.doi.org/10.1016/
